Washington D.C. 20549

                            Report of Foreign Issuer

                      Pursuant to Rule 13a-16 or 15d-16 of
                       the Securities Exchange Act of 1934

                         For period ending May 01, 2008

                               GlaxoSmithKline plc
                              (Name of registrant)

               980 Great West Road, Brentford, Middlesex, TW8 9GS
                    (Address of principal executive offices)

             Indicate by check mark whether the registrant files or
                 will file annual reports under cover Form 20-F
                                  or Form 40-F

                              Form 20-F x Form 40-F

         Indicate by check mark whether the registrant by furnishing the
        information contained in this Form is also thereby furnishing the
       information to the Commission pursuant to Rule 12g3-2(b) under the
                        Securities Exchange Act of 1934.

                                    Yes No x

                         Total Voting Rights and Capital

In conformity with Disclosure and Transparency Rule 5.6.1R,  GlaxoSmithKline plc
("the Company") hereby notifies the market of the following:

The  Company's   issued  share  capital  as  at  30  April  2008   consisted  of
5,866,590,834  Ordinary  shares  of  25p  each  with  voting  rights,  of  which
484,194,158 Ordinary shares are held in Treasury.

Therefore,  the total number of voting  rights in the Company is  5,382,396,676.
This figure may be used by shareholders as the denominator for the  calculations
by which they will  determine if they are required to notify their  interest in,
or a change to their  interest  in, the  Company  under the  Financial  Services
Authority's Disclosure and Transparency Rules.

S M Bicknell
Company Secretary

1 May 2008


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.

                                                             GlaxoSmithKline plc

Date: May 01, 2008                                      By: SIMON BICKNELL
                                                              Simon Bicknell
                                                 Authorised Signatory for and on
                                                   behalf of GlaxoSmithKline plc